CRISPR patent decisions could trigger waves globally (Lab Pulse)

In a surprise move, Nobel laureates Emmanuelle Charpentier and Jennifer Doudna are seeking to cancel two of their own key CRISPR patents in Europe. This decision follows a ruling that their initial patent application lacked enough detail for replication. The move aims to avoid a damaging legal precedent. The situation affects a broad network of biotech companies involved in CRISPR licensing and further complicates the ongoing CRISPR patent dispute between their team and the Broad Institute.